tiprankstipranks
Advertisement
Advertisement

AU:RCE Stock Latest News

Recce deepens U.S. Army ties and expands global patent reach in Q3 FY2026
Company AnnouncementsRecce deepens U.S. Army ties and expands global patent reach in Q3 FY2026
4d ago
Recce Clears Key Indonesian Inspection Milestone in Phase 3 Diabetic Foot Trial
PremiumCompany Announcements
Recce Clears Key Indonesian Inspection Milestone in Phase 3 Diabetic Foot Trial
13d ago
Recce Pharmaceuticals Options Lapse Trims Potential Share Dilution
PremiumCompany Announcements
Recce Pharmaceuticals Options Lapse Trims Potential Share Dilution
19d ago
Recce Wins Brazilian Patent for Broad-Spectrum Anti-Infective Portfolio
PremiumCompany Announcements
Recce Wins Brazilian Patent for Broad-Spectrum Anti-Infective Portfolio
1M ago
Recce Pharmaceuticals Issues Webinar Disclaimer on Investor Information and U.S. Offer Restrictions
PremiumCompany Announcements
Recce Pharmaceuticals Issues Webinar Disclaimer on Investor Information and U.S. Offer Restrictions
2M ago
Recce Pharmaceuticals Schedules Investor Webinar to Highlight Key Anti-Infective Programs
PremiumCompany AnnouncementsRecce Pharmaceuticals Schedules Investor Webinar to Highlight Key Anti-Infective Programs
2M ago
Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance
Premium
Company Announcements
Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance
2M ago
Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry
Premium
Company Announcements
Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry
2M ago
Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure
PremiumCompany Announcements
Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure
2M ago
Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study
PremiumCompany Announcements
Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study
3M ago
Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline
PremiumCompany Announcements
Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline
3M ago
Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline
PremiumCompany Announcements
Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline
4M ago
Recce Pharmaceuticals Secures A$85 Million R&D Tax Incentive for Global Anti-Infective Programs
PremiumCompany AnnouncementsRecce Pharmaceuticals Secures A$85 Million R&D Tax Incentive for Global Anti-Infective Programs
5M ago
Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives
Premium
Company Announcements
Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives
5M ago
Recce Pharmaceuticals Reports Promising Preclinical Results for Inhaled RECCE® 327
Premium
Company Announcements
Recce Pharmaceuticals Reports Promising Preclinical Results for Inhaled RECCE® 327
5M ago
Recce Pharmaceuticals Mourns the Loss of Founder Dr. Graham JH Melrose
PremiumCompany Announcements
Recce Pharmaceuticals Mourns the Loss of Founder Dr. Graham JH Melrose
6M ago
Recce Pharmaceuticals Ltd 2025 AGM Results Announced
PremiumCompany Announcements
Recce Pharmaceuticals Ltd 2025 AGM Results Announced
6M ago
Recce Pharmaceuticals Outlines Future Strategies at 2025 AGM
PremiumCompany Announcements
Recce Pharmaceuticals Outlines Future Strategies at 2025 AGM
6M ago
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infections in Indonesia
PremiumCompany Announcements
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infections in Indonesia
6M ago
Recce Pharmaceuticals Announces Director’s Interest Change
PremiumCompany AnnouncementsRecce Pharmaceuticals Announces Director’s Interest Change
7M ago
Recce Pharmaceuticals Announces Cessation of Securities
Premium
Company Announcements
Recce Pharmaceuticals Announces Cessation of Securities
7M ago
Recce Pharmaceuticals Completes Selective Buy-Back of Performance Shares
Premium
Company Announcements
Recce Pharmaceuticals Completes Selective Buy-Back of Performance Shares
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >